The Ahmedabad-based company has planned a capital expenditure of Rs 450 crore this fiscal. It has presence in the US, the European Union, Brazil, Mexico and exports generate half the revenue.
Homegrown drug major Zydus Cadila has set a target of clocking a consolidated turnover of over Rs 10,000 crore by FY'16.
"We will have a revenue of Rs 10,000 crore in FY16. We closed last fiscal with a revenue of Rs 7,208 crore," Zydus Cadila Chief Operating Officer and Executive Director Ganesh Nayak told PTI here.
The Ahmedabad-based company has planned a capital expenditure of Rs 450 crore this fiscal. It has presence in the US, the European Union, Brazil, Mexico and exports generate half the revenue.
Meanwhile, its consumer products arm Zydus Wellness , which makes the Sugar Free, is looking at a foray into adjacent categories like jams and biscuits in the future.
Also Read: Margins to scale up to 20% by FY15-end, says Dishman Pharma
The sweetener brand Sugar Free has a 93% market share in the sugar substitute category that is estimated at Rs 250 crore and growing at 12%.
"There is an opportunity to get into adjacent categories if you think of Sugar Free. So anything that is potentially served with sugar whether it is jam or biscuits or any product, could be substituted with a sugar-free version.
"The category penetration of sugar substitution per say where we are competing today is as low as 15%. There is lot of unfinished business and lot of growth to be had in current category. We are thinking about related categories and growth opportunities but we would rather address the immediate growth opportunity which lies within our range," Zydus Wellness Managing Director Elkana Ezekiel said.
Meanwhile, Ezekiel said the company is going slow on its low-calorie soft-drink Sugar Free D'lite, launched in 2003, as it is not doing well and is practically off shelf.
"In the overall scheme of things and in terms of percentage to our turnover, Sugar Free D'lite has been relatively small. We have not done much with it recently and we don't have an aggressive plan for it now. It is not a business where we could get to scale up and something we want to hold on to," Ezekiel said.
Zydus Wellness had reported a sales revenue of nearly Rs 430 crore last fiscal.
Its skincare brand EverYuth recently launched a facewash in Re 1 sachets and the company expects it would help in increasing sales in rural areas with its attractive pricing.
EverYuth enjoys a market share of 2.7% in the Rs 1,450-crore face wash segment, 91% in the peel off category that is valued at Rs 75 crore and 32% in the Rs 175 crore scrub category.
After getting off to a rocking start, EverYuth had gone on to become the second largest brand in the category in 2009 but has since slipped to a trickle.
Zydus Wellness stock price
On September 12, 2014, Zydus Wellness closed at Rs 640.30, down Rs 2.15, or 0.33 percent. The 52-week high of the share was Rs 676.20 and the 52-week low was Rs 435.00.
The company's trailing 12-month (TTM) EPS was at Rs 23.23 per share as per the quarter ended June 2014. The stock's price-to-earnings (P/E) ratio was 27.56. The latest book value of the company is Rs 83.32 per share. At current value, the price-to-book value of the company is 7.68.
Anda sedang membaca artikel tentang
Zydus Cadila sets Rs 10,000 cr sales target by FY16
Dengan url
https://citraasa.blogspot.com/2014/09/zydus-cadila-sets-rs-10000-cr-sales.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Zydus Cadila sets Rs 10,000 cr sales target by FY16
namun jangan lupa untuk meletakkan link
Zydus Cadila sets Rs 10,000 cr sales target by FY16
sebagai sumbernya
0 komentar:
Posting Komentar